Skip to main content

Hohl Benjamin's Form 4 filing

Enliven Therapeutics, Inc. (ELVN) · filed Oct 1, 2024

Accession no.
0001415889-24-024249
Filed
Oct 1, 2024
Trade date
Sep 27-30, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $153.8K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hohl BenjaminCIK 0001882764Officer (CHIEF FINANCIAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 27, 2024Common StockMOption exerciseAcquired+4,250$2.48+$10,5404,250Direct
Sep 27, 2024Common StockSSaleDisposed−4,250$24.27F2−$103,147.50Direct
Sep 30, 2024Common StockMOption exerciseAcquired+2,000$2.48+$4,9602,000Direct
Sep 30, 2024Common StockSSaleDisposed−2,000$25.33F3−$50,6600Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 27, 2024Common StockMOption exerciseDisposed−4,250$0.00$0194,879Direct
Sep 30, 2024Common StockMOption exerciseDisposed−2,000$0.00$0192,879Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $24.085 to $24.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $25.12 to $25.535. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)